SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

News Shanghai Shyndec Pharmaceutical Co., Ltd.

Stocks

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-07-16			5-day change	1st Jan Change
9.230 ^CNY	+1.54%		+7.83%	-8.61%

06-26	Shanghai Shyndec Pharmaceutical Gets China Regulatory Nod for Eye Drops	MT
06-16	Shanghai Shyndec Pharmaceutical Gets China Approval for Glaucoma Drops	MT

All News

Mentions Relevance

06-26	Shanghai Shyndec Pharmaceutical Gets China Regulatory Nod for Eye Drops	MT
06-16	Shanghai Shyndec Pharmaceutical Gets China Approval for Glaucoma Drops	MT
06-11	Shanghai Shyndec Pharmaceutical Co., Ltd.(SHSE:600420) dropped from Shanghai Stock Exchange Health Care Sector Index	CI
05-22	Shyndec Pharma Gets Registration Certificate for Ibrutinib Capsules	MT
04-29	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-13	Shanghai Shyndec Pharmaceutical Expects Up to 65% Decline in Q1 Attributable Profit; Shares Slide 6%	MT
04-07	Shanghai Shyndec Pharmaceutical Gets China Supplementary Drug Approval for Expectorant	MT
04-07	Shanghai Shyndec Pharmaceutical Gets Regulatory Approval for Kidney Drug	MT
03-27	Shanghai Shyndec pharmaceutical 2025 net profit down 13.1% Y/Y	RE
03-25	Shanghai Shyndec Pharmaceutical Acquires Muscle Relaxant Market Authorization for 10.5 Million Yuan	MT
02-25	Shyndec Pharmaceutical Gets China Approval for Antidepressant	MT
02-12	Shyndec Pharmaceutical Secures Bids For 51 Drugs in China's Latest Procurement Program	MT
02-09	Shyndec Pharmaceutical's Subsidiary Passes GMP Inspection	MT
01-27	Shanghai Shyndec Pharmaceutical's Attributable Profit Slides 13%	MT
01-26	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-13	Shyndec Pharmaceutical's Generic Drug Secures Approval for Antibiotic Consistency Evaluation	MT
12-26	Shyndec Pharmaceutical Gets China Nod for Antipsychotic	MT
12-12	Shyndec Pharma Gets Regulatory Approval for Cardiovascular Drug	MT
12-01	Shanghai Shyndec Pharmaceutical Gets Registration for Opioid Analgesic	MT
11-04	Shyndec Pharmaceutical Buys Rights for Lactulose Oral Solution	MT
25-10-29	Henan Yangsen Pharmaceutical Group Co., Ltd. completed the acquisition of an additional 51% stake in Shanghai Modern Hasen Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd..	CI
25-10-29	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-17	Henan Yangsen Pharmaceutical Group Co., Ltd. agreed to acquire an additional 51% stake in Shanghai Modern Hasen Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd. for approximately CNY 110 million.	CI
25-10-13	Shyndec Pharmaceutical's Unit Gets Nod to Market Sitagliptin Phosphate	MT
25-09-23	Shyndec Pharmaceutical's Subsidiary Gets Nod to Add Specification to Vitamin B6 Injection	MT